WY P&T Committee Meeting Minutes
Thursday, August 14, 2014
Cheyenne, WY
10 a.m. – 1 p.m.

Members present: Andrew Beaulieu, Joe Horam, Robert Monger, Garry Needham, Scot Schmidt, Brent Sherard, David Sy, Dean Winsch, Tonja Woods, Pat Yost

Excused: Stephen Brown

Ex-officio: Melissa Hunter, Cori Cooper, Donna Artery, James Bush

1. Guests: Nikki Yost (GHS), Amy Stockton (GHS), Brenda Stout, Sandra Deaver, Edie Dodson (Genzyme), Vince Lawler (Genzyme), David Stump (Amgen), Ted Sheedy (GSK), Melissa Houser (Novartis), Mort German (Novartis), Anne Marie Licos (Medimmune), Leslie Mann (Celgene), Dan McCaffrey (Vertex), Paul Bonham (NovoNordisk), Risa Reuscher (Amgen), Sandra Bellino (Mercke), Caroline Hoffman (Novartis), Carole Heumelgoia (Pfizer), Stephanie Soler, Bethany Reasch

Dr. Monger called the meeting to order at 10:04 a.m.

Introductions were made.

Approval of Minutes
The minutes of the May 8, 2014 meeting were approved as submitted.

Department of Health
A. Pharmacy Program Manager Report: The Pharmacy Program is currently working to revise the reimbursement structure used for outpatient drugs. This involves removing the federal upper limit (FUL) from the reimbursement methodology and applying additional maximum allowable costs (MAC) where applicable. The Preferred Drug List for 2015 is being drafted based on supplemental rebate offers available through the SSDC.

B. Medical Director Report: The State Plan Amendment (SPA) has been updated for Patient Centered Medical Home case management fees. CMS has about 60 days to comment or approve the plan and then the Department will begin these payments. There has been discussion regarding P&T Committee involvement in creating prior authorization criteria for J-codes.

C. DUR Manager Report: The retrospective review process will change beginning in the next quarter.

Old Business

A. Hepatitis C treatment: Comments from Dr. Peter Perakos regarding the
proposed Hepatitis C prior authorization criteria were reviewed. The use of the Metavir score will be removed from the general criteria. It will remain for requests to add Olysio to Sovaldi. To increase compliance, a patient readiness survey offered online will be required prior to approval and patients will be referred to Xerox CQS for case management services after approval.

There was a motion, second and all were in favor of the above changes.

New Business

A. PA Criteria
   1. Determine need for criteria
      i. No new business
   2. Review existing criteria:
      i. The existing criteria for Synagis was reviewed in comparison to the recently released AAP guidelines. Anne Marie Licos (MedImmune) provided public comment. She indicated that the safety data supports continued prophylaxis of patients in the 29 – 35 weeks gestation. Of the 92 patients treated in the previous RSV season, only 29 would qualify under the new guidelines. Dr. Horam suggested that Wyoming continue to treat this group and compare our outcomes to states in the region that conform to the new guidelines. He also suggested that we adopt the new guidelines for infants over 12 months old and for those who test positive for RSV despite prophylaxis. It was further recommended that these guidelines be reviewed annually.

   There was a motion, second and all were in favor of these recommendations.

   ii. Gilenya currently requires a step through interferon and Copaxone. Caroline Hoffman (Novartis) provided comment requesting that the Committee remove the step through interferon based on head to head superiority data over Avonex. She also indicated that there are no new safety signals after four years on the market. The Committee asked about cases of PML and the incidence of Zoster infection. There are nine cases of PML, eight of which had previous Tysabri exposure. The one patient on Gilenya without Tysabri exposure was not an MS patient and had been on high dose steroids. The cause of PML in this patient is unclear. It is Category C for pregnancy.

   There was a motion, second and all were in favor of allowing Gilenya following a trial of Copaxone only.

   iii. The immunomodulator class will be changing in 2015 with Enbrel and Humira being preferred. There was a motion, second and all were in favor of requiring trial and failure of both preferred agents prior to approval of a non-preferred agent.

3. New Drugs
i. Oralair, Ragwitek and Grastek were reviewed together given their similarities. The Immunologists in the state were consulted. There was a motion, second and all were in favor of limiting these medications to their specific indications and limiting to those who are not receiving allergy shots.

ii. Zontivity is a new antiplatelet agent that should be used in combination with clopidogrel or aspirin. There was a motion, second and all were in favor of limiting Zontivity to its indication.

iii. Sivextro is a new antibiotic that is unique in its approval for methicillin-resistant staphylococcus aureus. There was a motion, second and all were in favor of requiring trial and failure of two other antibiotics that cover MRSA or a culture indicating resistance to the other available agents.

B. Other: There was no other business.

There being no further business, the open portion of the meeting adjourned at 11:05 a.m.

During the closed session, the Committee reviewed potential candidates for the open position and chose a Nurse Practitioner to fill this position. The annual planning meeting was also held.

Aimee Lewis
WYDUR Manager